L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.
A 74-year-old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long-term treatment with 400 mg/day of L-dopa. Overnight sleep studies and multiple sleep latency testing were carried out under double-blind administration of either L-dopa or placebo. Mean sleep latency with L-dopa was 7 minutes, in contrast to a normal value of 19 minutes, 25 seconds with placebo. The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease.
Garcia-Borreguero
D
D
Department of Neurology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. dgarciaborreguero@fjd.es
Schwarz
C
C
Larrosa
O
O
de la Llave
Y
Y
Garcia de Yébenes
J
J
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006970:Disorders of Excessive Somnolence / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000097:blood; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000627:therapeutic use; D017286:Polysomnography / Q000379:methods; D011930:Reaction Time / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use
D000978:Antiparkinson Agents; D010479:Pergolide; D012642:Selegiline; D007980:Levodopa